Celeste MG, De Marco F, Fresco C, et al. Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation. Farmeconomia. Health Economics and Therapeutic Pathways. 2017;18(1). https://doi.org/10.7175/fe.v18i1.1327